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Strengths and limitations of this study
 ► The multimodal study design developed consensus- 
defined trial rating and complexity indicators to sup-
port objective analysis of cancer research delivery 
adaptable to operational evaluation in other thera-
peutic areas and global settings.
 ► Qualitative aspects provide in- depth contextual evi-
dence through the ‘voices’ of patient- facing profes-
sionals, articulating human and social aspects of 
research.
 ► This study is the first, to our knowledge, to present a 
Delphi methodology adopting a Singerian approach 
involving research professionals, in a consensus 
process which is holistic and dialectical.
 ► The study involved key stakeholders from a wide 
geographic base reflecting a heterogeneous sample 
of clinical trial professionals.
 ► Participants were limited to research professionals 
delivering studies at National Health Service sites in 
Scotland and England. Future research is planned 
involving a wider demographic to include sponsors, 
funders, networks and policymakers.
AbStrACt
Objectives To evaluate patient follow- up and complexity 
in cancer clinical trial delivery, using consensus methods 
to: (1) identify research professionals’ priorities, (2) 
understand localised challenges, (3) define study 
complexity and workloads supporting the development of a 
trial rating and complexity assessment tool (TRACAT).
Design A classic eDelphi completed in three rounds, 
conducted as the launch study to a multiphase national 
project (evaluating follow- up and complexity in cancer 
clinical trials).
Setting Multicentre online survey involving professionals 
at National Health Service secondary care hospital sites 
in Scotland and England varied in scale, geographical 
location and patient populations.
Participants Principal investigators at 13 hospitals 
across nine clinical research networks recruited 33 
participants using pre- defined eligibility criteria to form a 
multidisciplinary panel.
Main outcome measures Statements achieving a 
consensus level of 70% on a 7- point Likert- type scale and 
ranked trial rating indicators (TRIs) developed by research 
professionals.
results The panel developed 75 consensus statements 
illustrating factors contributing to complexity, follow- up 
intensity and operational performance in trial delivery, and 
specified 14 ranked TRIs. Seven open questions in the first 
qualitative round generated 531 individual statements. 
Iterative survey rounds returned rates of 82%, 82% and 
93%.
Conclusions Clinical trials operate within a dynamic, 
complex healthcare and innovation system where rapid 
scientific advances present opportunities and challenges 
for delivery organisations and professionals. Panellists 
highlighted cultural and organisational factors limiting the 
profession’s potential to support growing trial complexity 
and patient follow- up. Enhanced communication, 
interoperability, funding and capacity have emerged as key 
priorities. Future operational models should test dialectic 
Singerian- based approaches respecting open dialogue and 
shared values. Research capacity building should prioritise 
innovative, collaborative approaches embedding validated 
review and evaluation models to understand changing 
operational needs and challenges. TRACAT provides 
a mechanism for continual knowledge assimilation to 
improve decision- making.
IntrODuCtIOn
Clinical trial delivery in hospital settings is 
crucial in advancing cancer care and treat-
ment options with evidence indicating 
sustained commitment to research enhances 
performance and patient outcomes.1 Cancer 
research has evolved rapidly in recent years, 
with innovations in immunotherapy and 
precision medicine increasingly prioritised 
in healthcare policy. The National Health 
Service (NHS) has published ambitions to 
accelerate innovation, outlining a framework 
for rapid adoption of next generation treat-
ments offering personalised, stratified care 
and follow- up models.2 3
The ability to translate scientific, labora-
tory advances in cancer research into clinical 
and patient benefit through clinical trials is a 
critical requirement for healthcare providers, 
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as cancer incidence and patient populations continue to 
grow.4
Realising these translational benefits is challenging sites 
as cancer clinical research trial complexity increases,5 with 
niche designs and stratified treatments affecting research 
delivery costs and resources. Cancer research is an inter-
disciplinary enterprise advancing patient care and thera-
peutic benefits through a collaborative research pathway 
involving scientific, translational and clinical research 
trials. As trials evolve to study rare diseases, wide- ranging 
cancers and molecular sub- types, delivery complexity and 
workloads grow in tandem. Intricate protocols, narrow 
selection criteria, high data demands and extended 
safety, efficacy and outcome monitoring6 7 are stretching 
staff and site capabilities.
A predicted 70% increase in cancer incidence8 within 
20 years combined with improving survival rates, follow- up 
demands and funding pressures necessitates operational 
review of trial designs and implementation frameworks 
to articulate impacts on sites, patients and professionals. 
Systematic, structured evaluation of research delivery in 
secondary care (hospital) settings is limited with minimal, 
current empirical study of trial complexities and follow- up 
impacts, workloads, institutional dynamics or operational 
processes across complex healthcare institutions such as 
the NHS. In- depth review is a paramount priority for the 
healthcare industry to comprehend variables contrib-
uting to service pressures, identify changing stakeholder 
needs and facilitate evidence- based commissioning of 
services through appropriately aligned funding and 
support models.
Delivering research in the era of precision medicine is 
intense and complex, a clinical reality strongly evidenced 
in international literature.9 Analysis of operational delivery 
involving key delivery stakeholders has predominantly 
operated at regional levels, limiting global relevance 
and has not yet led to transformative models.10 Lyddiard 
et al11 undertook a UK collaborative study to develop a 
workload measurement tool but excluded investigator 
and pharmacist roles, anticipating challenges in collating 
accurate workload data. Further research recommended 
qualitative evaluation of workload and complexity along-
side development of trial rating models using experts 
whose advice is ‘fundamental to the weighting and 
scoring’.12 However, within healthcare applications and 
systems development there is a persistent lack of dialogue 
with ‘users and implementers of technology for data 
capture’.13 Operational evaluation including assessment 
of technologies, training solutions, capacity planning and 
research delivery models should involve subject- matter 
experts capable of providing grounded knowledge and 
insight. The significant complexity gap and incremental 
patient follow- up activity requires external recognition. 
Currently there is no national analysis of follow- up or 
protocol complexity workloads to understand fluctuating 
operational and resource demands at local, regional and 
national levels. Systematic rating of trial attributes in real 
time and over study lifetimes will create longitudinal data 
sets enabling evidence- based cost attribution and funding 
decisions to enhance research capacity and produc-
tivity. The extant literature underlines a need for broad, 
cyclical and continual analysis of research advancements 
and disease burdens to anticipate future demands for 
resources, as well as facilitating sustainable growth, 
productivity and improvements in patient care.
Enabling research growth necessitates structured 
workforce planning; yet there is poor application of this 
crucial management function across the NHS.14To build 
capacity, manage increasingly complex trials and support 
patient- centred care, research organisations, funders 
and policymakers need to evaluate current delivery 
and performance management models, seek interdis-
ciplinary stakeholder feedback and consider adopting 
creative, design- thinking approaches with reflective and 
critical capabilities.15Research into Singerian organi-
sational models has shown that holistic and dialectic 
approaches to understanding context- related challenges 
support process improvement and knowledge genera-
tion. Organisations cultivating positive communication 
with well- integrated systems are associated with improved 
performance and healthcare outcomes.16 Holistic, collab-
orative team environments promote valued attributes of 
respect, creativity and knowledge sharing.17
AIMS
Cancer research forms part of a complex collaboration 
between scientists, clinical research professionals and 
patients. Evaluation of patient follow- up in cancer clin-
ical trials and the nature of complexity, in its many forms, 
need to understand the experiences and challenges of 
research professionals’ implementing and delivering 
cancer clinical trials in hospital settings. In this study we 
aimed to contribute to existing knowledge of transla-
tional cancer research, to support acceleration of labo-
ratory advances for patient benefit, by engaging research 
professionals in a democratic, systemic evaluation of 
cancer clinical trial research delivery. We sought multi-
disciplinary perspectives to: (1) identify research profes-
sionals’ priorities, (2) understand localised challenges, 
(3) define study complexities and workloads supporting 
the development of a trial rating and complexity assess-
ment tool (TRACAT). This study adopted a holistic, 
consensus- based design engaging patient- facing clinical 
trial professionals in developing grounded, contextual 
knowledge of trial implementation and end- user input 
into the development of TRACAT which will function 
as an operational decision- support tool, as well as high-
lighting views, perceptions and priorities for their profes-
sional field.
MethODS
Study design and approach
To facilitate a detailed systems evaluation sensitive to 
the multi- faceted nature of cancer research delivery a 
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multimodal study was developed. The design reflects the 
Singerian- Churchmanian model of inquiring systems 
(SCIS) valuing ethics and community knowledge in 
complexity evaluation and decision- making.18 The 
adopted design combining the Delphi technique with 
a Singerian approach followed an initial scoping review 
covering subject, policy and methodological literature. 
The review identified key challenges for the profession 
directing the overall research and initial survey design. 
A democratic approach was needed recognising multiple 
perspectives combined with individual knowledge and 
experience, to form a comprehensive understanding of 
the complexities of the systems and networks in which 
they operate through a dialectical group consensus 
process, a Singerian Delphi. SCIS provide a framework 
and meta- method approach to generating actionable 
knowledge, capable of addressing wicked, complex prob-
lems and ‘sensemaking in complex, multifaceted, subjec-
tive’19 contexts.
Delphi technique
The Delphi technique is widely used in healthcare to gain 
insight from front- line experts knowledgeable within 
specific fields.20 It provides practical applications in 
consensus development, prioritisation, forecasting, policy 
development and investigation of multi- faceted issues.20–22 
We adopted the method to elicit expert opinion in devel-
oping a comprehensive rubric of research delivery vari-
ables and in the analysis of complex problems within a 
group.23 Healthcare and research delivery operate within 
complex adaptive systems with diverse and multifarious 
units, processes and interactions. Analysis of complexity 
concepts provides an explanatory, sensemaking device 
to interpret ‘phenomena in diverse applications’24 which 
are dynamic, emergent and entwined. The professionals 
recruited to the panel performed an ethical role, as their 
observations and engagement in identifying trial- rating 
attributes contribute to designing an evaluation tool for 
operational decision- making and strategic planning. The 
design of technical applications or models for strategic 
evaluation or decision support and inclusion criteria 
for measurement or quantitative judgements should be 
based on input from ‘experts’ in the field (patients and 
professionals), the users and benefactors of ‘human- 
centred automation'.13 17 23For this reason, the research 
commences with a Delphi designed from a Singerian 
inquiring system perspective, drawing ethics and heuris-
tics into the development of an information system and 
model.25 This Singerian- oriented Delphi aimed to incor-
porate diverse knowledge, experience and ideologies of 
multiple stakeholders, disciplines and personality types26 
to form a prismatic view of cancer research delivery sensi-
tive to its evolving, multi- faceted and complex nature.27
Sampling procedure
A purposive selection process recruited NHS secondary 
care (hospital) sites from a wide geographic base in the 
UK. This supported formation of an ‘expert’ panel of 
professionals, knowledgeable in delivering research at 
teaching, acute or district general hospitals providing 
services to rural and metropolitan patient populations. 
Site characteristic diversity, based on scale and nature of 
operations and patient populations, aimed for a hetero-
geneous sample minimising bias and facilitating expres-
sion of ranging perspectives. To achieve a target sample 
(n=20) researchers planned to recruit between 22 and 
30 participants. While this is a relatively small sample size 
the importance in the selection of a Delphi sample is the 
knowledge and expertise of participants in relation to the 
research. The interdisciplinary nature of research and 
delivery roles required a range of professionals to form 
an expert panel. A smaller sample size is effective when 
panellists are similarly knowledgeable and expert in the 
field of study.28
recruitment procedure
Principal investigators at sites approached potential 
participants based on their knowledge and experience 
within cancer research delivery. Pre- defined eligibility 
criteria stipulated professionals should have 18 months 
experience in secondary care setting within a research 
delivery or support role, currently or within the past 18 
months.
Materials and survey design
The three- round eDelphi took place online between 
January and August 2018 using Qualtrics software. Partic-
ipant information sheets described the iterative process, 
commencing with open questions in round 1 and moving 
to structured questions in subsequent rounds. The anony-
mised design meant participants’ identity was unknown 
to other panellists, a key benefit of the technique.29 
Anonymity facilitates free and open expression of indi-
viduals removing the potential for domination by senior 
or influential colleagues which may lead to bias as partic-
ipants submit to peer pressure within an open group.30 
References to roles within individual textual responses 
were removed, protecting participants’ anonymity and 
preventing role seniority influence on consensus develop-
ment. Consenting participants received an invite and link 
to the online questionnaire. Detailed instructions guided 
panellists throughout with individual feedback provided 
between rounds. Experts were encouraged to complete 
surveys as fully as possible to facilitate comprehension 
of perspectives, priorities and levels of consensus and 
support reliability of results. Optional free- text comments 
at the end of each question section and survey encour-
aged dialogue, reflection and refinement of observations. 
The roles of participants and their ethical contribution 
were detailed in the study information sheets and docu-
ments provided to participants who consented to join the 
‘expert panel’.
First round survey
Panellists provided their definitions, perceptions and 
suggestions to seven open questions shown in table 1. 
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Table 1 First round open questions
Q1. Follow- up definition The term ‘follow- up’ in clinical trials can have different interpretations dependent on the role of the 
researcher. Please provide your definition of the term ‘follow- up’ in relation to cancer clinical trials.
Q2. Barriers and 
burdens
Please describe the phenomena you encounter in your role within cancer clinical research, which you 
perceive as barriers or burdens to effective trial implementation and delivery. Please feel free to list as 
many issues or concepts as you wish. These could relate to local, departmental or regional factors as 
well as cultural, resource and study design elements.
Q3. Complexity Please provide your analysis of complexity in terms of delivering cancer clinical trials. This could 
include the complex nature of the disease or interactions involved in managing the treatment and 
care pathway for a cancer patient participating in a clinical trial. Please feel free to suggest as many 
themes as you wish.
Q4. Capacity factors Please describe factors affecting your capacity to support and deliver cancer clinical trials within the 
NHS. These can be elements relative to your specific role, organisation or more global factors. Please 
list as many considerations as you wish.
Q5. Top priorities Please suggest your top three strategic priorities for the future delivery of cancer clinical trials in the 
NHS.
Q6. Effective practice Please provide your views on existing elements of cancer clinical research practice within the NHS, 
which contribute to or demonstrate efficient trial delivery and practice.
Q7. Additional 
considerations
Please add any additional elements you feel should be considered by the Delphi panel in relation to 
reviewing the operational delivery, follow- up and complexity of cancer clinical trials.
NHS, National Health Service.
The broad nature of questions aimed to generate 
rich responses iteratively testing inter- connection of 
phenomena between categories. Individual responses 
were analysed in NVivo with responses coded themati-
cally. Similar themes were condensed into the initial 201 
group statements with care taken to retain as much of 
participants’ intended meaning as possible. Participants 
were advised that themes suggested by the panel would 
be developed as trial rating indicators (TRIs) as part 
of the TRACAT tool to support workforce and capacity 
planning.
Second round survey
Panel- developed statements were circulated alongside a 
7- point Likert- type scale ranging from strongly disagree 
(1) to strongly agree (7), for participants to confirm their 
level of agreement to question category statements from 
1 to 7. A new survey section (question 8) asked panel-
lists to rank TRACAT categories from lowest priority (1) 
to highest priority (7) as factors to include as TRIs and 
complexity indicators. To form the initial TRI categories 
first round responses were coded in NVivo and ranked by 
frequency of themes.
third round survey
Panellists received the previous round’s results showing 
the percentage level of agreement and median response 
to each statement alongside their own selection. Panellists 
were asked to review initial responses in light of levels of 
agreement and either revise or leave their original selec-
tion unchanged, following reflection on wider perspec-
tives. Participants were encouraged to comment on 
reasoning for changing responses by more than two scale 
points away from consensus, or their original selection. 
Final round panellists received a summary report of 
consensus statements and ranked TRACAT categories.
Data analysis
The qualitative data from the open round were content 
analysed and coded thematically in NVivo using a frame-
work approach to create the initial complexity cate-
gories in question 8. The statements relative to each 
individual question category are shown in table 1. A 
second stage of hand coding to validate the initial analysis 
was performed. Quantitative analysis of the second and 
third round Likert- type scale responses was performed 
using SPSS V.22.0. Summary statistics reported to panel-
lists described frequency of responses to statements 
(percentage level) and the median (measure of central 
tendency). In addition the IQR was used as a measure 
of dispersion in analysing stability of responses and move 
towards consensus in order to decide on the final survey 
iteration.
Consensus level and validity
Consensus was defined as 70% of panellists rating a 
statement the same on the 7- point Likert- type scale, a 
recognised level of agreement.31 Instructions advised 
participants that a convergence of opinion and the 
agreed consensus measure would determine the stopping 
point for the study. Items achieving frequency consensus 
and median strength of agreement contribute to future 
questionnaire and interview designs.
Patient and public involvement
A patient advisory group reviewed the study design prior 
to submission to HRA (Health Research Authority) 
and ethics with revisions made following their 
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Table 2 Participant demographics and response rates by round
Characteristic
Round 1 Round 2 Round 3
n % n % n %
Gender             
  Male 4 14.81 4 14.81 3 12.00
  Female 22 81.48 22 81.48 21 84.00
  Other 1 3.70 1 3.70 1 4.00
Age             
  25–34 3 11.11 3 11.11 2 8.00
  35–44 9 33.33 9 33.33 9 36.00
  45–54 10 37.04 10 37.04 9 36.00
  55–64 5 18.52 5 18.52 5 20.00
Years in clinical research             
  Between 2 and 5 years 8 29.63 9* 33.33 9 36.00
  Between 5 and 10 years 11 40.74 11 40.74 9 36.00
  More than 10 years 8 29.63 7 25.93 7 28.00
Role             
  Research and development manager 4 14.81 3 11.11 3 12.00
  Research nurse 8 29.63 9 33.33 8 32.00
  Research nurse manager 2 7.41 2 7.41 2 8.00
  CI, PI or co- investigator 3 11.11 3 11.11 3 12.00
  Data manager 2 7.41 2 7.41 2 8.00
  Clinical/senior clinical trials practitioner 3 11.11 3 11.11 2 8.00
  Finance business partner 1 3.70 1 3.70 1 4.00
  Research nurse and PI 1 3.70 1 3.70 1 4.00
  Research support officer 1 3.70 1 3.70 1 4.00
  Research radiographer 1 3.70 1 3.70 1 4.00
  Research pharmacy technician 1 3.70 1 3.70 1 4.00
Total participants 27   27   25   
*One participant joined the study in round 2.
CI, chief investigator; PI, principal investigator.
recommendations. Panellists received a final consensus 
report and other stakeholders had the option to receive 
results by a preferred method of print, email, Qualtrics 
or evaluating follow- up and complexity in cancer clinical 
trials (EFACCT) website; https:// efacct. com/.
reSultS
The target sample (n=20) was exceeded with 33 profes-
sionals from 13 hospitals and 9 local research networks 
consenting to join the expert multidisciplinary panel. 
Forty- four potential participants were approached with 
11 professionals declining due to limited capacity or 
availability to complete the surveys. The summary demo-
graphics and return rates are shown in table 2. Twenty- 
five research professionals completed the three- round 
process, an increase of 25% on the initial planned 
sample, compensating for a 24% participant dropout rate. 
Regular communication with panel members encouraged 
retention but robust return rates and continued commit-
ment potentially suggest the study’s importance in 
providing a platform to elucidate role- specific experi-
ences and challenges. The number of panel statements 
generated in the opening round within each question 
category is detailed in table 3 alongside the percentage 
of statements achieving consensus by each category and 
round.
round 1 survey results
Round 1 achieved a return rate of 81.82% with 27 partic-
ipants completing the initial qualitative survey and 
demographic information. Open question responses 
were comprehensive leading to the generation of 531 
individual statements, analysed and condensed into 201 
group statements.
round 2 survey results
Round 2 achieved the same response with 15 statements 
reaching consensus (7.46% of total statements). One 
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Table 3 Consensus statements by question category and round
Question category 
(n)
Question category 
(%)
Statements in 
category (n)
Total panel 
statements (%)
Round 2 performance
  Q1. Follow- up definition 1 25.00 4 0.50
  Q2. Barriers and burdens 6 13.04 46 2.99
  Q3. Complexity 1 2.86 35 0.50
  Q4. Capacity factors 1 2.17 46 0.50
  Q5. Top priorities 2 5.88 34 1.00
  Q6. Effective practice 4 15.38 26 1.99
  Q7. Additional Delphi considerations 0 0.00 10 0.00
  Round 2 totals 15 — 201 7.46
Round 3 performance
  Q1. Follow- up definition 1 25.00 4 0.47
  Q2. Barriers and burdens 21 45.65 46 9.81
  Q3. Complexity 10 28.57 35 4.67
  Q4. Capacity factors 9 19.57 46 4.21
  Q5. Top priorities 23 67.65 34 10.75
  Q6. Effective practice 9 34.62 26 4.21
  Q7. Additional Delphi considerations 1 4.30 23 0.47
  Round 3 totals 75 — 214 35.05
participant joined the panel for the quantitative survey 
rounds. They did have the option to provide individual 
feedback through free- text comments in line with all 
other participants.
round 3 survey results
Twenty- five panellists returned the final survey, a return 
rate of 92.59%. This round included 13 additional state-
ments generated from free- text responses. Table 3 details 
the 75 statements reaching consensus. In addition, 14 
TRIs were identified with four achieving a median rating 
of 7 (highest priority) and remaining items rated as 6 
or 6.5. Non- responders to round 2 were not included in 
the third circulation. Based on the groups’ move towards 
consensus the third survey formed the final round.
Summary of panel responses and discourse
The results provide detailed insights into factors contrib-
uting to complexity, follow- up intensity and resource 
impacts for sites. The researchers chose to retain the 
broad nature of participant statements following data 
collection of the initial qualitative open round. As a 
criterion of the Singerian Delphi, professional panel-
lists needed to witness the diversity, depth and richness 
of colleague responses, and the complexity of problems 
in social settings. In retaining detailed statements the 
full nature of participants’ sentiments in responses is 
expressed, allowing the Delphi panel the opportunity to 
reflect on broader perspectives, concepts and nuances of 
meaning. Characterising a Singerian inquiring approach 
the Delphi study served as a process for adding to 
‘substantive knowledge’ and ‘participants’ knowledge of 
themselves’ through a group reflective process.23 Partic-
ipant feedback was encouraged throughout, supporting 
the concept of the Delphi as a self- reflective and collec-
tive decision- making process, whereby there is a move 
towards consensus, or a participant’s conscious informed 
choice to revise their opinion or personal philosophy 
based on wider perspectives of peer group experiences. 
Panellists described changes in their perspectives stem-
ming from a new understanding of ‘how things may be’ in 
different contexts or ‘in light of more recent experiences 
and discussion’. Other feedback illustrated the nature of 
changing circumstances and experiences on perceptions 
and sensitivities during the course of the study, leading to a 
reflection and adjustment of initial views and recognising 
the subjective nature of issues. Statements achieving the 
highest levels of agreement are detailed under each ques-
tion category. Online supplement 1 presents the full list 
of panel consensus statements.
Follow-up definition
Participants provided personal definitions of ‘follow- up’ 
in relation to cancer clinical trial delivery. Responses 
highlighted diverse interpretations with 56% of panellists 
defining follow- up as activities relating to any or multiple 
protocol stages (including active and post- treatment 
phases) while 44% identified follow- up as occurring solely 
post- active treatment.
Panellists confirmed their level of agreement to 
summarised definitions of follow- up created from 
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Table 4 Q1 Follow- up definition consensus statement
Median 
response
Consensus 
% level
1.4 NIHR/nationally agreed 
definition of follow- up: A 
nationally agreed definition 
of the term 'follow- up' 
and/or types of 'follow- 
up' in relation to research 
delivery in the NHS should 
be published by the NIHR 
so that all clinical research 
professionals, allied 
professions and associated 
bodies conform to a 
standard terminology and 
parameters.
Strongly 
agree (7)
92
NHS, National Health Service; NIHR, National Institute for Health 
Research.
individual interpretations to form three core categories: 
(1) any trial stage, (2) multiple stages, (3) post- active treat-
ment. An additional question in round 2 asked panellists 
to consider the need for a nationally agreed definition 
supporting research delivery. Panel- developed definitions 
did not reach consensus but 92% of professionals strongly 
agreed on a need for a nationally agreed definition of the 
term and its sub- types (table 4).
barriers and burdens
In round 1 the panel described phenomena encountered 
in their roles within research and elements perceived as 
barriers or burdens to effective practice. This category 
reached high levels of agreement with 21 statements 
achieving consensus, the highest of which called for an 
‘effective and consistently validated funding and support 
model’, recognising increased levels of complexity within 
cancer clinical trials and associated workloads. Panellists 
agreed strongly (92% consensus) that the funding of 
research delivery does not ‘accurately reflect the require-
ments, time and effort of sites’ representing a risk for 
NHS organisations in delivering effective research with 
inadequate resources and staffing levels (table 5).
Analysis of complexity
The highest level of consensus within the study was 
reached in this category with 96% of professionals strongly 
agreeing growing protocol burden adds to operational 
complexity (table 6). Ten statements in this domain 
reached consensus, 60% of which had a consensus level 
of over 80%. A further 11 statements in this group were 
in a 10% range of consensus sharing over 60% agreement 
levels between panellists.
Factors affecting capacity
In round 1 the panel described factors affecting their 
capacity to support and deliver cancer trials. Nine state-
ments reached consensus with the highest item level of 
agreement (88%) alluding to organisational inadequa-
cies in communication, collaboration and integration 
across services, impeding the effectiveness of trial delivery 
(table 7).
Strategic priorities
The largest number of consensus statements by category 
related to strategic priorities with 23 items reaching an 
agreement level of 76% or higher. Five statements shared 
panel consensus of 88% in terms of their priority for 
research delivery, four of which related to social aspects 
of operations: cognition, collaboration and communica-
tion (table 8).
effective research practice
Panellists provided views on existing elements of cancer 
clinical research practice in the NHS they felt contributed 
to or demonstrated efficient trial delivery and practice. 
Statements achieving consensus and a median response 
of strongly agree in this category related to human- 
centred elements of research delivery with seven state-
ments reaching 80% agreement levels or above (table 9).
Additional Delphi considerations
A final broad category provided participants the opportu-
nity to suggest additional items for panel consideration. 
Existing categories incorporated related statements but 
themes which were new, unique or covered multiple areas 
were presented in section 7. Free- text responses provided 
by panellists generated 23 statements with one achieving 
consensus (table 10).
trACAt—trial rating and complexity assessment tool
First round statements were coded thematically within 
NVivo creating a matrix of codes which were quanti-
fied by frequency of themes to form the initial trial 
complexity analytical categories of question 8. The 14 
TRIs (complexity scoring statements) were prioritised 
by panellists from lowest priority (1) to highest priority 
(7). Table 4 shows the panel ranking of TRIs which will 
be used to develop the TRACAT tool. The indicators and 
rankings are detailed in table 11.
DISCuSSIOn
Overview of main findings
The Delphi’s primary aim was to evaluate cancer clinical 
research delivery with a focus on patient follow- up and 
complexity from a multidisciplinary perspective. The 
study provides in- depth insights of professionals working 
at the forefront of cancer clinical trial delivery, identifying 
priorities, concerns and indicators of research complex-
ities. Consensus and priority factors developed by expert 
panellists illustrate tensions and pressures within the 
profession. The main findings are discussed in relation 
to the key objectives across the eight inter- related survey 
categories with cross- over themes.
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Table 5 Q2 Barriers and burdens—top consensus statements
Median
Consensus % 
level
2.19 Trial sites are under constant pressure to open trials with expectations to 
recruit high numbers of trial participants to increasingly complex and higher 
intensity trials treating patients with rare cancers while being faced with 
reduced resources. Budgetary constraints and outdated payment terms that 
do not accurately reflect the requirements, time and effort of sites represent 
a high risk to NHS organisations where audited and reduce the capacity to 
maintain effective trial delivery and meet patient needs through inadequate 
staffing levels. The NIHR needs to acknowledge the increased complexity 
of cancer trials, the workload impact in coordination and management, 
augmented lab work and data management demands and comprehend the 
nature of academic and commercial trials and their associated pressures on 
research delivery sites and staff through the development of an effective and 
consistently validated funding and support model.
Strongly agree (7) 92
2.35 The management of patient follow- up in cancer studies is a key factor 
affecting site capacity and ability to implement, recruit to and deliver effective 
research. Follow- up visits for cancer patients and research studies can 
continue for many years and often until death. Patients may also transfer from 
other hospitals for follow- up care, which has an impact on the research staff 
and capacity at site. Follow- up data are essential to the outcomes of research 
studies but the NIHR research delivery model focuses on and supports 
recruitment but not follow- up activities. With continual pressure to open 
studies to gain accruals the ability of teams to manage existing numbers of 
patients in follow- up is compromised leading to missed timelines, patient 
visits and missing data, which could be extremely detrimental to follow- up 
studies and invalidate results of the trial. These burdens and issues are not 
recognised within research delivery.
Strongly agree (7) 88
2.13 PI oversight and involvement are lacking at times in certain tumour sites, 
studies or hospital locations, particularly for multi- site trusts where the PI 
works from one centre, leaving research nurses feeling unsupported. When 
new studies are set up it is important to ensure there is a clear understanding 
of roles and responsibilities of the research team so that workloads can be 
accurately assessed. PIs should be aware that they could delegate tasks 
according to GCP but retain overall responsibility for the study beyond the 
treatment elements and need to maintain involvement in patient follow- up and 
review.
Strongly agree (7) 88
2.4 Support and retention of research professionals, nurses and specialist roles 
as well as the provision of sufficiently skilled resource should be the focus of 
the NIHR and trusts to ensure safe and efficient research environments and 
reduce excessive workloads. Staff turnover, changes, sickness and absence 
all have a significant impact on research implementation and delivery at sites.
Strongly agree (7) 84
2.23 Protocols and study documentation supplied to assess capacity and 
capability do not show the impact of eCRFs or the full extent of information 
and demographic data required. High data demands and the management 
of sponsor data queries are a significant and time- consuming administrative 
burden for sites. Difficulties in communication or slow responses can 
lead to extended or additional work for sites especially where a sponsor's 
representative does not comprehend the problems in obtaining retrospective 
information or understand the nature of certain data issues.
Strongly agree (7) 84
eCRF, Electronic case report form; GCP, Good clinical practice; NHS, National Health Service; NIHR, National Institute for Health Research; 
PI, principal investigator.
evaluating follow-up and complexity
Follow- up definition: Patient follow- up in cancer clinical 
trials is a key factor affecting capacity to deliver research, 
requiring an ostensive definition to ensure support models 
for its effective management develop from a clarified and 
equitable stance. The meaning participants attached to 
follow- up varied significantly which has implications for 
operational review. Implementation of a funding model 
acknowledging resource implications in patient follow- up 
management reached consensus as a strategic priority. 
 o
n
 February 25, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034269 on 18 February 2020. Downloaded from 
9Jones HM, et al. BMJ Open 2020;10:e034269. doi:10.1136/bmjopen-2019-034269
Open access
Table 6 Q3 Analysis of complexity—top consensus statements
Median
Consensus 
% level
3.21 Cancer clinical trial protocols have varying degrees of complexity but the burden of 
protocol procedures is growing which adds to the complexity of implementing and 
delivering studies, with incremental levels of training (eg, 450 training slides on a five 
arm study with strict guidelines) and increased volumes of tests, questionnaires, visits, 
assessments and more detailed data requirements.
Strongly 
agree (7)
96
3.1 Cancer is no longer one diagnosis but a complex range of conditions with many 
subgroups. Cancer clinical research complexity is growing as trials now study a wide 
range of cancers, rare tumours, haematological malignancies and molecular sub- types 
with treatments becoming precise, targeted and having more options at each stage 
of the cancer journey. Trials may now only be suitable for a subgroup of the cancer 
population such as lymphoma, which has more than 70 sub- types. Sites need to have a 
greater number of trials open to ensure patients have the opportunity to participate, but 
each trial will recruit a smaller number of patients adding to the complexity of delivering 
research.
Strongly 
agree (7)
92
3.17 Managing the communication and coordination of clinical trial appointments, procedures 
and diagnostics, for example, mammography, ECHO, ECGs, clip insertion, CT scans, 
bone marrow and surgical/specialist procedures are pressurised and complicated when 
liaising with multidisciplinary teams and support services to meet protocol specific time 
frames or treatment windows. Aligning a study with the 2- week wait or fitting it into a 
surgical pathway isn't always possible due to operational problems and capacity issues.
Strongly 
agree (7)
88
3.6 The clinical trial phase is a key determinant in study complexity with earlier phase 
studies typically more complex, requiring lots of visits, extra tests or PK analysis. 
Early phase clinical trials frequently need input from other departments for 
example, ophthalmology or dermatology requiring collaboration to arrange time and 
appointments. Studies involving overnight stays can be hard to organise due to bed 
and resource capacity. Admitting patients for trial monitoring can be hard to justify and 
negotiate when beds are full. Later stage studies such as phase 3 may include standard 
of care but complexity is added due to the larger volume of patients required and 
lengthy follow- up.
Strongly 
agree (7)
88
3.16 Protocol designs that involve short timelines and windows for procedures are more 
complex and logistically challenging for sites to deliver when trying to schedule 
registration, randomisation, assessments and treatment around the availability of NHS 
resources, especially where there is little flexibility from the sponsor. It can be difficult 
when a patient is excluded from a trial because of scan timings or initial bloods not 
having been taken by other clinicians who saw the patient first at diagnosis, but not as 
part of a trial. Additional complexities arise from late diagnostics where a patient comes 
to the centre late.
Strongly 
agree (7)
80
ECHO, Echocardiogram; NHS, National Health Service; PK, Pharmacokinetics.
Panellists strongly agreed that managing follow- up was a 
key factor affecting capacity, calling for recognition of the 
challenges faced and intimating the National Institute for 
Health Research (NIHR) recruitment focused delivery 
model does not support follow- up. The group expressed 
a view that follow- up data are essential to successful trial 
outcomes but felt under pressure to open new studies to 
gain accruals, with a detrimental effect on their ability to 
support existing patients.
Barriers and burdens: A common thread running through 
statements on barriers and burdens within research was 
an expression of sites being under pressure, with percep-
tions of high expectations and demands placed on staff 
while faced with reduced resources. Communication 
issues, both internally and externally, were a common 
theme and perceived as a barrier to effective research. 
Concerns also related to sponsor documentation and 
inadequacy of information to accurately assess capacity 
and capability, or determine the full impact of delivering 
a study, in terms of its associated workloads and adminis-
trative burden. High levels of agreement between panel-
lists indicated a sense of feeling unsupported, indicating 
principal investigator oversight and involvement can be 
lacking at times, recommending a clear understanding 
of roles, responsibilities and accurate assessment of 
workloads.
Analysis of complexity: In addition to incremental inter-
ventions, tests and procedures within evolving study 
designs, the panel highlighted factors relating to the 
nature of cancer as a complex disease. Wide- ranging 
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Table 7 Q4 Factors affecting capacity—top consensus statements
Median
Consensus 
% level
4.2 Effective communication is the golden thread, which ensures an organisation can work 
effectively. The lack of integration, communication and collaboration across hospital 
sites and departments impacts trial delivery.
Strongly 
agree (7)
88
4.4 Inadequate resources and facilities affect the capacity of research staff to conduct their 
jobs to the standards expected.
Strongly 
agree (7)
88
4.3 Inadequate staffing levels make it difficult for teams to meet the demands of current 
trials and to run as efficiently and effectively as possible.
Strongly 
agree (7)
84
4.45 Protocols, which are overly complicated, do not realistically work with hospital systems 
or have been written in such a way that they are hard to interpret impact capacity and 
efficiency. Studies with well- written protocols that consider the practicalities of trial 
delivery are much easier for sites to run.
Strongly 
agree (7)
84
4.46 The increasing complexity of new cancer trials and protocols can be challenging for 
sites to deliver and therefore detailed feasibility is essential, but the implications of 
running the study is not always apparent at the outset as frequent or unnecessary 
amendments can impact the capacity of the team as the study progresses.
Strongly 
agree (7)
84
Table 8 Q5 Top strategic priorities—top consensus statements
Median
Consensus 
% level
5.13 Decision makers at national and local levels require a greater level of understanding of 
the constraints, resource and capacity issues and the priorities for research delivery and 
funding in the NHS.
Strongly 
agree (7)
88
5.2 Development of biomarkers for predicting suitability and response to treatment and early 
diagnosis techniques.
Strongly 
agree (7)
88
5.20 Promote cultural change and education to raise the profile of research and highlight the 
importance of clinical trials in the provision of cancer care within the NHS.
Strongly 
agree (7)
88
5.22 Ensure development of strong working relationships and rapport between research teams 
and supporting departments.
Strongly 
agree (7)
88
5.6 Improve collaboration and communication between trusts and organisations (including non- 
NHS care providers such as hospices) to ensure patient care and choice are prioritised and 
all are given the opportunity to participate in research, where desired and appropriate.
Strongly 
agree (7)
88
NHS, National Health Service.
sub- types and niche patient populations combined 
with variations in health status and support needs of 
patients add to research complexity. While trial phase 
is a recognised contributor to complexity, participants 
frequently cited short timelines and visit windows for 
protocol procedures as being problematic, particularly in 
terms of aligning sponsor requirements to site capacity, 
treatment pathways and the coordination of procedures, 
multidisciplinary teams and support services.
Factors affecting capacity: Strong consensus existed 
between research professionals with regard to capacity 
factors. Inadequacies in staffing levels, funding, resources 
and facilities featured alongside constraints relating 
to overly complicated protocols designed without due 
consideration for practicalities of research delivery. 
Frequent amendments to trials also affected ongoing 
capacity reflecting uncertainty within research delivery 
which cannot always be predicted at site feasibility.
Strategic priorities: Participants strongly agreed on stra-
tegic priorities relating to culture, education and collabo-
rative relationships, all social aspects of research delivery. 
A patient- focussed priority reached an 88% consensus on 
the requirement to develop biomarkers for prediction of 
suitability and response to treatment and early diagnosis. 
The panel came to the same level of consensus in respect of 
national and organisational recognition of the challenges 
faced by professionals and sites. A group perspective illus-
trated the need for local and national leaders to develop 
greater understanding of the ‘constraints, resource and 
capacity issues and the priorities for research delivery 
and funding in the NHS’. The high levels of consensus 
relating to environment, culture, education, resources 
and investment delineate the needs of a profession within 
an evolving healthcare system, providing a strong focus 
for the NIHR and policymakers and impetus for further 
dialogue and review.
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Table 9 Q6 Effective research practice—top consensus statements
Median
Consensus 
% level
6.17 Good communication skills and effective patient relationships help participants 
understand the trials and what participation will mean for them.
Strongly 
agree (7)
88
6.2 Well run, established departments and research teams who receive regular training 
are efficient, proactive, flexible to change and demonstrate a wealth of knowledge and 
excellence in clinical trial delivery.
Strongly 
agree (7)
84
6.14 Principal investigators who proactively support and engage with the research team are 
available to provide advice when required, maintain oversight on their trials, including 
follow- up visits and discussion of treatment plans, ensure that trials are run effectively 
and safely in their research area.
Strongly 
agree (7)
80
6.18 Effective practice is demonstrated by dedicated staff who are willing to go above and 
beyond to recruit and support patients in clinical trials. Caring and skilled research 
professionals who treat patients as individuals and not just as a recruitment figure are 
appreciated by patients who value their support, and continue on the trial for follow- up 
visits and are less likely to withdraw from studies.
Strongly 
agree (7)
80
6.21 The provision of dedicated teams and specialists for specific cancer disease areas/
sites within trial units enhances research delivery and staff knowledge in their specialty, 
in contrast to stretching resources across multiple specialisms.
Strongly 
agree (7)
80
Table 10 Q7 Additional Delphi considerations—consensus 
statements
Median
Consensus 
% level
7.3 Supporting the primary 
endpoints of clinical trials 
should be the main goal of the 
NIHR and follow- up should be 
appropriately funded to achieve 
this.
Strongly 
agree (7)
72
NIHR, National Institute for Health Research.
Effective research practice: Themes of open communica-
tion, staff commitment and dedication, well- trained and 
informed staff and strong collaborative teamwork all 
achieved high levels of consensus between the Delphi 
panellists. These skill sets within the profession allow sites 
and research staff to share best practices, retain staff and 
contribute to efficient trial delivery despite current chal-
lenges and resource limitations.
Additional Delphi considerations: The one statement 
achieving consensus in this category called for appro-
priate follow- up funding to support the primary endpoints 
of clinical trials.
TRACAT: A key outcome of the study is the ranking of 
TRIs to develop TRACAT, a system- based tool facilitating 
the accurate mapping and monitoring of factors deter-
mining study intensity, workload and resource impact on 
trial centres. The trial complexity rating will be applied to 
studies to support sites in feasibility assessment and map 
any changes to workloads or complexity during study 
life- cycles. Key stakeholder knowledge is vital in devel-
oping operational evaluation models and panellists had 
an important study role in prioritising and ranking TRIs 
and recommending additional factors for consideration. 
Through the assignment of a trial rating and complexity 
score linked to monitoring of interventions, visits, 
follow- up and patient volumes TRACAT provides work-
load and capacity analysis at individual, site, regional 
and national levels. The aim is to create an objective trial 
rating and portfolio management tool capable of inte-
grating with existing data systems, to monitor real- time 
activity linked to complexity, increasing the value and 
structure of data for strategic and operational decision- 
making. Enhanced knowledge of trial complexity and 
acuity will support forecasting and capacity planning to 
optimise resource allocation in line with research objec-
tives and patient needs.
Strategic opportunities for clinical research delivery: The study 
identified shortfalls at local and national levels, relating to 
effective communication and shared comprehension of 
needs and priorities for research, which provide an imme-
diate opportunity for service improvements through 
better engagement across networks, organisations and 
disciplines. Strategic opportunities exist for trusts, local 
research networks, the NIHR and NHS to work collabo-
ratively to develop specialist services and support models, 
built on shared understanding and structured opera-
tional evaluation, to increase patient ‘accessibility, choice 
and participation in clinical trials’. To improve research 
quality and safety it is essential healthcare providers 
promote open and honest cultures focusing on improve-
ment.32 Professionals and organisations alike need to 
embrace dialectic approaches where mutual respect, inno-
vation and communication can thrive. Iterative dialogue 
with research professionals to understand critical values 
and perceptions, relevant to local contexts, is vital in iden-
tifying effective strategic models and measures to improve 
operational delivery.33 There is no national workforce 
planning for research delivery and NHS global activities 
for workforce modelling are fragmented.34 As research 
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Table 11 Trial Rating Indicators (TRIs) priority rankings
Rank Q no TRI category 1 (lowest priority)–7 (highest priority) Priority % Median
1 8.2 Protocol procedures—treatments, interventions, tests, samples and their volumes, 
frequencies and timelines.
72 7
2 8.1 Resource demands—feasibility and personnel impact. 72 7
3 8.7 Investigational treatment complexity—drug administration, novel therapy/drug, 
toxicity and risk, treatment windows and timelines.
64 7
4 8.5 Follow- up and visit requirements—type, frequency and duration. 60 7
5 8.3 Data management, administration and monitoring—sponsor defined requirements. 48 6.5
6 8.4 Support department involvement and outsourcing—support services (trust/external), 
for example, RECIST reporting, QA procedures, specialist skills, facilities, equipment, 
central review or sub- contracted requirements.
48 6
7 8.8 Clinical efficacy and safety—clinical pharmacology and pharmacokinetics 
requirements.
44 6
8 8.11 Patient management—patient monitoring, safety, reporting or complex patient 
pathways.
44 6
9 8.12 Patient selection—patient identification, screening, eligibility criteria and consent 
process.
36 6
10 8.6 Cancer disease complexity, patient population and health status 32 6
11 8.13 Trial phase and design—randomisation process, multiple treatment arms, blinding, 
study phase
28 6
12 8.10 Recruitment potential—recruitment feasibility and target potential by disease and 
study type.
24 6
13 8.14 Technology and training—sponsor defined requirements for study. 24 6
14 8.9 Protocol variations—protocol amendments, study extensions and ancillary/sub- 
studies.
16 6
QA, Quality assurance; RECIST, Response Evaluation Criteria in Solid Tumours; TRIs, trial rating indicators.
advances and organisations grow, they face increasing 
challenges and complexities. Dynamic, fluctuating and 
evolving environments call for greater understanding 
of context- specific challenges. This study highlights the 
current realities of research delivery, emphasising the 
importance of dialogue and shared decision- making 
in developing effective strategies and common goals, 
respecting mutual understanding.
Evaluating research delivery and performance: Analysing 
and measuring performance and quality in evolving 
professions and organisations is challenging. Richardson 
et al17 argue that an organisation’s measurement of infor-
mation decreases in value as they grow and face greater 
complexity. Evaluation of operational performance and 
monitoring of success need to take into account not only 
objective measures but also understand and value quali-
tative evidence to indicate progress or success, especially 
where complexity of operational elements is a dominant 
characteristic. Regular evaluative research of the state 
and nature of the clinical research delivery industry in 
the UK should be an ethical requirement of the NHS, 
NIHR and their partners. There is a moral obligation for 
researchers to ensure that the work they undertake and 
the resource allocated to perform these activities provide 
value, efficiency in service and participant benefit.
Singerian inquiry in operational review: An effective 
evaluation of trial delivery requires a systems approach 
engaging multidisciplinary professionals from a wide 
range of geographical locations, networks and trusts in 
a collective critique covering multiple realms. Collab-
orative research cultures supporting enhanced data 
structuring and synthesis can ‘significantly shorten the 
time gap between clinical research results to better clin-
ical care decisions’.35 The nuances and complexities 
of cancer research delivery necessitated a study design 
involving a critical analysis of strategies, processes and 
technologies through a collation and synthesis of pris-
matic perspectives and experiential data. This study 
supports a systems- based approach to developing effec-
tive research capacity planning and performs an ethical 
role in the review of current NHS research delivery with 
the intent of improving performance and patient expe-
rience. An adaptive NHS research delivery framework 
capable of analysing and monitoring research capacity 
and operational models in real- time and over time would 
enhance knowledge and support strategic planning. This 
study contributes in- depth qualitative review into oper-
ational aspects of clinical trials by engaging key stake-
holders in defining variables relating to service pressures 
as well as highlighting best practices.
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Relation to existing research: Our findings support the 
existing body of research documenting increasing pres-
sures on sites linked to protocol complexity. Growing 
patient populations, bespoke therapies and extended 
follow- up pose challenges for existing NHS strate-
gies with resources and research professionals under 
increasing pressure. The ability to grow research capacity 
is limited in systems where performance measures do 
not adequately assess complexity and context or support 
‘tailored research capacity- building interventions’.33 Clin-
ical research operational delivery exists within a complex 
adaptive system faced with growing challenges, one that 
Britnall argues ‘requires us to think, work and collaborate 
in different ways’.34 Outdated, hierarchical management 
styles36 and cognitive dissonance are fuelling a health-
care staffing crisis and stifling innovation through its 
alienation of experienced, knowledgeable and creative 
professionals. Britnall discusses the following four key 
domains where improvement and investment enhances 
productivity: workforce health and well- being, skills 
development, technological efficiencies and effective 
innovation.34 Findings of our study reinforce the need for 
strategic focus in these domains.
Strengths and limitations
A strength of the study is the holistic, dialectical, 
consensus- based design which is as far as we are aware the 
first use of a Singerian Delphi in cancer research evalua-
tion. Qualitative aspects of the design provided in- depth 
grounded knowledge through the ‘voices’ of clinical trial 
professionals, articulating human and social aspects of 
research delivery. The study also developed consensus- 
defined TRIs and complexity indicators to support objec-
tive analysis of cancer research delivery, adaptable to 
other therapeutic areas and global settings.
Given the exploratory nature of the study in devel-
oping a Singerian focused qualitative Delphi the resulting 
data sets were lengthy and expressive. The causal rela-
tionships within the data sets were not fully analysed 
during the implementation of the Delphi study. The 
EFACCT Delphi findings contribute to the development 
of grounded theory as part of a wider national project 
being conducted by the research team. This democratic 
study developed new knowledge in defining areas of 
importance to research delivery stakeholders and forms 
part of an iterative research programme to evaluate and 
support operational delivery, focusing on follow- up and 
complexity.
Participants were limited to patient- facing professionals 
delivering studies at NHS sites in Scotland and England 
and did not include representatives from the Clinical 
Research Network. The results reflect the perspectives 
of professionals conducting the delivery elements of 
cancer research at trial sites. This does provide a strong 
understanding of the priorities in a clinical setting but 
enhanced knowledge covering the full gamut of roles 
within the industry is required. This Delphi forms part 
of a programme of study with future research planned 
involving a wider demographic to include sponsors, 
funders, networks and policymakers.
Implications for practice
The results point to operational fragmentation and 
organisational disconnect with conflicting priorities 
limiting the ability of the profession to manage growing 
complexities and pressures. The evidence suggests that 
the current operating model is not sustainable for NHS 
sites. Statements achieving the highest level of consensus 
between Delphi panellists outlined growing protocol and 
procedural burden, calling on the NIHR to acknowledge 
increased complexities in cancer clinical trials and associ-
ated pressures for sites. High levels of consensus relating 
to operational challenges in research are relevant to 
wider global settings and the concepts should be tested 
in other therapeutic areas. Additional recommendations 
included the requirement for a nationally agreed defini-
tion of follow- up and an effective, consistently validated 
funding and support model.
The research design considered the suitability of the 
Singerian approach within the Delphi method in rela-
tion to answering the main research question. A Singe-
rian Delphi can serve multiple purposes and answer 
complex and broad questions in a single study. Our 
approach demonstrates a pragmatic application of the 
Singerian Delphi through an engagement with multiple 
perspectives to develop collaborative knowledge37 and a 
recognition of diversity and complexity in understanding 
separate realities. Retrospectively, based on the resultant 
data and reflection, the Singerian approach has emerged 
as a potential theoretical lens to apply in future research 
investigating operational management within healthcare 
organisations.
COnCluSIOnS
Cancer clinical research delivery forms part of a complex 
system which is in perpetual flux and ill- suited to linear, 
determinate operational models and processes. Disease, 
humans and operational networks, all complex in their 
own respect, continually transpose, synthesise and evolve, 
requiring a prismatic perspective and adaptive, systems- 
thinking approach to comprehend and to design effective, 
sustainable, human- centred research delivery solutions.
In summary, our findings indicate that in order to 
support patient access to clinical trials, meet national 
research ambitions and keep pace with scientific advances 
in cancer research, a delivery model cognisant of complex 
and diverse contextual challenges is required. To deliver 
quality research the holistic needs of patients and profes-
sionals alike need supporting. Further research into oper-
ational efficacy should consider the testing of dialectic 
models based on the Singerian approach. While the study 
applied the Singerian approach as a Delphi method-
ology, it has emerged as a highly appropriate approach to 
understand and manage the dynamic and evolving field 
of cancer clinical research as a whole.
 o
n
 February 25, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034269 on 18 February 2020. Downloaded from 
14 Jones HM, et al. BMJ Open 2020;10:e034269. doi:10.1136/bmjopen-2019-034269
Open access 
AcknowledgmentsThe authors wish to acknowledge the invaluable contribution 
of principal investigators and staff at United Lincolnshire Hospitals Trust, Edinburgh 
Cancer Centre, Dumfries & Galloway Royal Infirmary, Clatterbridge Cancer Centre, 
University College London Hospitals NHS Foundation Trust, Royal Devon & Exeter 
NHS Foundation Trust, Harrogate & District NHS Foundation Trust, Derby Teaching 
Hospitals NHS Foundation Trust, University Hospitals Coventry & Warwickshire, 
Aintree University Hospitals NHS Foundation Trust, Lancashire Teaching Hospital 
NHS Foundation Trust, North Bristol NHS Trust, and Poole Hospital NHS Foundation 
Trust.
Contributors HMJ was responsible for the study design, data acquisition 
and analysis and led on manuscript preparation. FC contributed to manuscript 
preparation, review and revision. GL provided statistical review. FC, GL, CB and TA 
were responsible for academic and intellectual review of the study design, protocol 
and manuscript. DB has provided clinical oversight. All authors have read and 
reviewed the final manuscript.
Funding United Lincolnshire Hospitals NHS Trust (through cancer charitable 
funds) and the University of Lincoln funded a PhD studentship leading to the study. 
University of Lincoln as sponsor provided academic and research governance 
direction.
Competing interests None declared.
Patient consent for publication Not required.
ethics approval The study was approved by the East Midlands—Derby Research 
Ethics Committee (reference: 17/EM/0292) and the University of Lincoln School of 
Health and Social Care Ethics Committee. All participants taking part in the Delphi 
study provided informed consent.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request. 
Anonymised data will be available on request from the corresponding author.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
OrCID iD
Helene Markham Jones http:// orcid. org/ 0000- 0002- 4881- 4973
reFerenCeS
 1 Downing A, Morris EJ, Corrigan N, et al. High Hospital research 
participation and improved colorectal cancer survival outcomes: a 
population- based study. Gut 2017;66:89–96.
 2 NHS England. Improving outcomes through personalised medicine, 
2016. Available: https://www. england. nhs. uk/ wp- content/ uploads/ 
2016/ 09/ improving- outcomes- personalised  medicine. pdf [Accessed 
16 June 2019].
 3 NHS. The NHS long term plan, 2019. Available: https://www. 
longtermplan. nhs. uk/ online- version/ [Accessed 12 Aug 2019].
 4 Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 
2018: GLOBOCAN estimates of incidence and mortality worldwide 
for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
 5 Malik L, Lu D. Increasing complexity in oncology phase I clinical 
trials. Invest New Drugs 2019;37:519–23.
 6 National Cancer Policy Forum. Policy Issues in the Clinical 
Development and Use of Immunotherapy for Cancer Treatment: 
Proceedings of a Workshop. National Academies Press (US), 2016. 
Available: https://www. ncbi. nlm. nih. gov/ books /NBK396430/ 
[Accessed 01 Aug 2019].
 7 Gilbert MR, Rubinstein L, Lesser G. Creating clinical trial designs 
that incorporate clinical outcome assessments. Neuro Oncol 
2016;18:ii21–5.
 8 Stewart BW, Wild CP. World cancer report 2014. IARC Publications, 
2014. Available: https:// publications. iarc. fr/ Non- Series- Publications/ 
World- Cancer- Reports/ World- Cancer- Report- 2014 [Accessed 12 Jul 
2019].
 9 Janiaud P, Serghiou S, Ioannidis JPA, et al. New clinical trial designs 
in the era of precision medicine: an overview of definitions, strengths, 
weaknesses, and current use in oncology. Cancer Treat Rev 
2019;73:20–30.
 10 Getz KA, Kaitin KI, Kenneth K. Open innovation: the new face 
of pharmaceutical research and development. Expert Rev Clin 
Pharmacol 2012;5:481–3.
 11 Lyddiard J, Briggs J, Berridge J, et al. A workload measurement. 
Appl Clin Trials 2010 (Accessed 12 Jul 2019).
 12 Briggs J, Lyddiard J, Coffey M, et al. When to say ‘Yes’ in the NHS: 
Development of a Complexity Scoring System & Management Tool. 
CR Focus 2011;22:19–22.
 13 Batchelor J. The assumptions of data capture. J Clin Stud 
2017;9:46–7.
 14 Alderwick H, Dixon J. The NHS long term plan. BMJ 2019;364:l84 
https:// doi. org/ 10. 1136/ bmj. l84
 15 Paquet G, Ragan T. Through the Detox prism: exploring 
organisational failures and design responses. Ottawa: Invenire Books, 
2012: 119–23.
 16 Vaughn VM, Saint S, Krein SL, et al. Characteristics of healthcare 
organisations struggling to improve quality: results from a systematic 
review of qualitative studies. BMJ Qual Saf 2019;28:74–84.
 17 Richardson SM, Courtney JF, Paradice DB. An assessment of the 
Singerian Inquiring organizational model: cases from academia and 
the utility industry. Inf Syst Front 2001;3:49–62 https:// link. springer. 
com/ article/ 10. 1023% 2FA% 3A1011449620792
 18 Haynes JD. Internet management issues: a global perspective. 
London: IGI Global, 2012: 167–9.
 19 Paul D. Addressing Complex Decision Problems in Distributed 
Environments. In: van Gigch JP, ed. Wisdom, knowledge, and 
management. C.West Churchman and related works series. Springer, 
New York, NY, 2006: vol 2. 85–6.
 20 Akins RB, Tolson H, Cole BR. Stability of response characteristics of 
a Delphi panel: application of bootstrap data expansion. BMC Med 
Res Methodol 2005;5:37.
 21 Kennedy HP. Enhancing Delphi research: methods and results. J Adv 
Nurs 2004;45:504–11.
 22 Critcher C, Gladstone B. Utilizing the Delphi technique in policy 
discussion: a case study of a Privatized utility in Britain. Public Adm 
1998;76:431–49.
 23 Linstone HA, Turoff M. The Delphi method: techniques and 
applications. Newark, NJ: New Jersey Institute of Technology, 
2002: 167–9. https:// web. njit. edu/~ turoff/ pubs / delphibook. pdf. 
(Accessed 11 Sep.18).
 24 Courtney J, Merali Y, Paradice D, et al. On the study of complexity in 
information systems. IJITSA 2008;1:37–48.
 25 Mozuni M, Jonas W. An Introduction to the Morphological Delphi 
Method for Design: A Tool for Future- Oriented Design Research, She 
Ji: The Journal of Design, Economics. and Innovation 2017;3:303–18.
 26 Mitroff II, Williams J, Rathswohl E. Dialectical inquiring systems: 
a new methodology for information science. J Am Soc Inf Sci 
1972;23:365–78.
 27 Saukko P. Doing research in cultural studies: an introduction to 
classical and new methodological approaches. London: SAGE 
Publications, 2003: 25–7.
 28 Keeney S, McKenna H, Hasson F. The Delphi technique in nursing 
and health research. 53. First Edition. Oxford, UK: Wiley, 2011.
 29 Hsu C, Sandford BA. The Delphi technique: making sense of 
consensus. Prac Ass Res Eval 2007;12:1–8.
 30 Keeney S, Hasson F, McKenna HP. A critical review of the Delphi 
technique as a research methodology for nursing. Int J Nurs Stud 
2001;38:195–200.
 31 Vernon W. The Delphi technique: a review. Int J Ther Rehabil 
2009;16:69–76.
 32 HRA. Uk policy framework for health and social care research v3.3, 
2017. Available: https://www. hra. nhs. uk/ planning -and-improving-
research [Accessed 12 Aug 2019].
 33 Edwards N, Kaseje D, Kahwa E. Building and Evaluating Research 
Capacity in Healthcare Systems: Case Studies and Innovative 
Models. Cape Town: UCT Press, 2016: 31.
 34 Britnell M. Human: solving the global workforce crisis in healthcare. 
London: Oxford University Press, 2019.
 35 Batchelor J. Strength through collaboration. Int Clin Trials 
2017;9:24–6.
 36 West M. The NHS crisis of caring for staff: what do we need to do? 
kings fund, 2019. Available: https://www. kingsfund. org. uk/ blog/ 2019 
/03/nhs-crisis-caring [Accessed 06 Sep 2019].
 37 Greenhalgh T, Jackson C, Shaw S, et al. Achieving research impact 
through co- creation in community- based health services: literature 
review and case study. Milbank Q 2016;94:392–429.
 o
n
 February 25, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034269 on 18 February 2020. Downloaded from 
